Click to Share

Filter News
Show All Results
News By Country
News By Tag
Serotonin Remove

January 2020

Public Company News

Business Press Releases

Serotonin Press Releases

Exclusive News
Topics Locations Industries Dates

By Neurolixis, Inc.
Neurolixis Inc. has been awarded funds by the US Department of Defense to test its drug candidate, NLX-112, in a preclinical model of Machado-Joseph disease (MJD), a rare and disabling inherited movement disorder.
By Neurolixis Inc.
The Neurolixis lead compound, NLX-112, is at the heart of a brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, a.k.a.

Page updated every 10 minutes

Like PRLog?
Click to Share